Time-limited venetoclax and ibrutinib for patients with R/R CLL and undetectable MRD
Prof. Carsten Niemann, Department of Clinical Medicine, University of Copenhagen, Denmark
In this podcast, Prof. Carsten Niemann discusses the primary analysis of the Randomized Phase II Vision HO141 Trial. This study looked into time-limited venetoclax and ibrutinib treatment for patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) and undetectable minimal residual disease.
SUBSCRIBE TO BJH HEMATALKS SERIES